{"id":617356,"title":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) - Overview - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-03-03","captureTimestamp":"2026-03-03T06:04:01.315000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-clinical-practices/guidance-documents/guidance-drugs-clinical-trials-human-subjects-gui-0100.html","snippet":"Part C, Division 5 of the Food and Drug Regulations \"Drugs for Clinical Trials Involving Human Subjects\" (GUI-0100): Overview Overview Application and authorization Good clinical practices Labelling and records Submission of information and samples Serious unexpected adverse drug…","rawSnapshotUrl":"/api/snapshots/raw/617356","browseUrl":"https://replay.healtharchive.ca/job-6/20260303060401/https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-clinical-practices/guidance-documents/guidance-drugs-clinical-trials-human-subjects-gui-0100.html#ha_snapshot=617356","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}